JPMorgan Chase has completed the rotation this note has tracked for three weeks: the defensive options overhang that dominated June has largely unwound, and the stock has responded by clearing $334 — up roughly 9% over the past month.
The clearest development this week is in the put/call ratio. Options traders have moved to their least defensive posture in months. The PCR now reads 1.15, nearly one full standard deviation below the 20-day mean of 1.27 — a sharp reversal from the 52-week high of 1.47 hit on June 15. The arc is clean: the ratio ran at elevated levels through late May and peaked as the stock rallied through $320, then has compressed steadily since — 1.44 on June 8, 1.37 by mid-June, and now 1.15. That z-score of -1.05 marks the most bullish options configuration in this cycle. The hedging that seemed to chase the rally has been unwound.
Short positioning tells a consistent and unexciting story. Bears hold just 1.05% of the free float short — trivially low for a bank this size. Short interest edged down roughly 2.4% on the day and is flat on the week after picking up about 11% over the past month, likely reflecting modest macro hedging rather than conviction. Borrow remains extremely loose: availability is essentially unconstrained, with over 2.3 billion shares available to lend. Cost to borrow is 0.29%, up from a mid-May floor below 0.10% but still in the noise for a stock of this liquidity. There is no short squeeze risk and no meaningful crowding in either direction.
Analyst targets cluster just above the current price, suggesting the Street is not dramatically ahead of the tape. The mean target runs near $343, with bulls at Evercore ISI and Piper Sandler holding Outperform ratings with targets around $340–$345 — both raised after the Q2 earnings beat in April. Hold-rated analysts at Truist and Jefferies sit at $320–$332, modestly below the current price. That spread between the Holds and Outperforms is narrow; the debate is less about direction and more about valuation headroom. The stock carries a P/E near 14.2x and a P/B of 2.3x, both up roughly 5–11% over the past month as the rally repriced multiples. Forward earnings momentum remains the bull case anchor — the 12-month forward EPS growth factor ranks in the 76th percentile. Bears point to potential credit cost normalisation and deposit competition, which the bull_bear case flagged as the key pressure point heading into Q3.
The exec-level selling is consistent and worth noting, though not alarming. General Counsel Friedman sold just over $1.8m in shares on June 22, a repeat of a similar-sized sale in May. A cluster of C-suite disposals hit on May 15 — division CEOs Erdoes and Lake, CIO Beer, and subsidiary CEO Petno all sold between $950k and $2m — followed by COO Piepszak, CFO Barnum, and CRO Bacon selling on May 5. All are routine compensation-plan disposals with low significance scores; net insider activity over 90 days is marginally positive at $104m largely due to the share count, not meaningful buying. There is no insider accumulation to frame as a catalyst signal.
Among peers, JPM has led the group's week but not by a dramatic margin. BAC added 3.7% and USB rallied 3.9%, both outperforming WFC's more modest 1.2% gain. The sector tone is broadly constructive, and JPMorgan's relatively tighter correlation to C — which slipped 0.5% on Tuesday — suggests the stock is benefiting from its diversified revenue mix rather than a pure rate-beta trade.
With Q2 results scheduled for July 14, the setup heading into that print is what to watch next: whether the PCR continues to compress toward neutral or rebuilds protective positioning in the three weeks of pre-earnings tape between now and then.
See the live data behind this article on ORTEX.
Open JPM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
